Unlocking the Power of Blood-Based Biomarkers in ALS: From Discovery to Clinical Impact
Time: 8:30 am
day: Conference Day One
Details:
- Explore how Simoa® technology is enabling ultra-sensitive detection of biomarkers like Neurofilament light chain (NfL) to monitor ALS progression and treatment response
- Gain real-world insights into how NfL is being used in clinical trials to support patient stratification, therapeutic monitoring, and trial design
- Understand the future of personalized ALS care through the integration of fluid biomarkers into research, diagnostics, and disease management
